🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Honored to share our article in the NEJM Breast Cancer Update, discussing two perspectives on anthracycline use in breast cancer—a long-debated topic that remains highly relevant today Grateful to co-author this work with Prof. Martine Piccart OncoAlert

The new ZAP-IT study is evaluating the safety and effectiveness of #Azenosertib (ZN-c3) in combination with carboplatin and pembrolizumab in metastatic #TripleNegativeBreastCancer. For more information call 877-338-7425 or visit: dana-farber.org/clinical-trial… PI: Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 #TNBC

Check out this recent commentary from Drs. Megan Tesch (Megan E. Tesch), Douglas Drachman (Douglas Drachman) and Erica Mayer (Erica Mayer) on preventative #Oophorectomy and young women at risk. sciencedirect.com/science/articl…

Congratulations to Adrienne Waks, MD, (Ada Waks), Associate Director of Clinical Research Dana-Farber’s Breast Oncology Center, on this prestigious George P. Canellos Award for Excellence in Clinical Investigation! Dana-Farber News Harvard Medical School

Wow. I am so grateful for our BC community for supporting our good friend and colleague ⁦Aditya Bardia, MD⁩ and his family during this terrible time. Please donate!! Fundraiser by Mina Sedrak : Support the Bardia Family After Palisades Fire. gofundme.com/f/bardia

Erica Mayer of Dana-Farber shares insight on responses with preoperative niraparib plus dostarlimab in patients with BRCA-mutant, ER-positive, HER2-negative #breastcancer. Read more here: onclive.com/view/neoadjuva…

SERENA-6: ctDNA guided approach to switching from AI to camizestrant upon development of ESR1m in combo with cdk4/6i demonstrates improvement in PFS! PFS2 + OS immature Could be a paradigm shift + could introduce ctDNA monitoring into practice astrazeneca.com/media-centre/p…

Important publication on the #pallas trial! Thank you @angiedemichele Erica Mayer for a great global collaboration. SG About Medicine Outcomes in stage IIA versus stage IIB/III in the PALLAS trial ABCSG-42/AFT-05/PrE0109/BIG-14-13 Breast Cancer Research …ast-cancer-research.biomedcentral.com/articles/10.11…

Check out the #ASCO25 Central Nervous System Tumors poster session on Saturday for a presentation by Guilherme Nader-Marta, MD (Guilherme Nader Marta) and learn about the efficacy of immune checkpoint inhibitors in patients with #CNS metastases from solid tumors. Abstract 2024 | Poster

Join us at #ASCO25 tomorrow to discuss the efficacy of immune checkpoint inhibitors in patients with CNS metastases from solid tumors, a group often overlooked in clinical trials Soraia Lobo-Martins Diogo Martins Branco Evandro de Azambuja, MD, PhD Marco Tagliamento Elisa Agostinetto Eva Blondeaux Matteo Lambertini, MD PhD

Congrats to Dr Ian Krop Yale Cancer Center on the Bonadonna Award, honoring his practice-changing work in breast cancer! Wonderful introduction from Eric Winer, MD. Critical importance of: -mentorship -industry collabs -investigator initiated trials -funding -family

Dr. Erica Mayer (Erica Mayer) presented results from the #TRADEstudy at #ASCO25, which showed that an initial dose escalation strategy for adjuvant #abemaciclib allowed a greater number of early-stage HR+/HER2- #BreastCancer patients to reach and maintain 150 mg BID dosing at

#ASCO25 #MetastaticBreastCancer Poster Session: Assessing the impact of #ScalpCooling in patients receiving #TrastuzumabDeruxtecan for metastatic #BreastCancer. Elahe Salehi DNP Abs 1095 | Poster Bd 74 | Jun 2, 9-12 PM CDT | Hall A

.Erica Mayer, MPH, presents a poster on RYZ101 (²²⁵Ac-DOTATATE) in ER+/HER2 - advanced #breastcancer after prior therapy - early results from the phase 1b/2 TRACY-1 study show promise. #ASCO25

With ASCO25 wrapping up, I wanted to acknowledge the impact of a person that— between leading Dana-Farber’s Breast Oncology Center, caring for patients, mentoring countless physicians, parenting 2 teenagers — also led 2 trials that will impact lives for thousands of pts globally. Congrats Sara Tolaney!

Inavolisib triplet approval marks real progress for pts w/ PIK3CA-mut HR+ mBC With progress come new questions—on pt selection, toxicity & integration into practice In this article we break down the data and its implications doi.org/10.1200/OA-25-… Dana-Farber’s Breast Oncology Center OncoAlert

The #HarvardBreastCancerCourse starts on Thursday! 📅July 17 & 18 📍Westin Copley Place, Boston, MA The Harvard Medical School #BreastCancer course is well suited for medical, surgical & radiation oncologists; breast & general surgeons; internists; physician assistants; nurse practitioners,

Amazing discussion during the Harvard University Course tumor board on MBC. The rapidly increasing number of available treatment options complicates algorithms, raises opportunities for debate, and most importantly, improves patients’ outcomes. Exciting days for breast cancer treatment.

Dr. Erica Mayer (Erica Mayer) started off Session VI on #ERpositive breast cancer with a comprehensive review of new treatment approaches in early ER+ #BreastCancer. She discussed adjuvant #CDK 4/6 inhibitors, neoadjuvant IO for HR+ disease, and oral #SERDs.

After CDK4/6 Inhibitors: Advancing Treatment for HR+HER2-negative Metastatic Breast Cancer— Mafalda Oliveira, Erica Mayer, and Shom Goel will address this topic in an educational session at #SABCS25 (December 9-12). brnw.ch/21wUjob Mafalda Oliveira Erica Mayer Shom Goel